Publications

A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma

GK Abou-Alfa, M Capanu, EM O’Reilly, J Ma, JF Chou, B Gansukh, J Shia, ...

A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic …

D Li, S Pant, DP Ryan, D Laheru, N Bahary, T Dragovich, PJ Hosein, ...

A single-arm, non-randomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma

EM O'Reilly, A Perelshteyn, WR Jarnagin, M Schattner, H Gerdes, ...

A woman with metastatic pancreatic neuroendocrine tumor

AN Shoushtari, AM Covey, G Zaatari, A Shamseddine, AS Epstein, ...

APACT: A phase 3 randomized, open-label, multicenter trial evaluating the use of adjuvant nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients …

MA Tempero, DB Cardin, A Biankin, D Goldstein, M Moore, EM O'Reilly, ...

APACT: A Phase III Trial of Nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) Versus Gem Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (PC): 232

M Tempero, D Cardin, A Biankin, D Goldstein, M Moore, E O’Reilly, ...

APACT: a Phase III Trial of nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) vs Gem Alone as Adjuvant Therapy for Patients (pts) with Resected Pancreatic Cancer (PC)

MA Tempero, D Cardin, A Biankin, D Goldstein, M Moore, EM O'Reilly, ...

APACT: A phase III trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone for resected pancreatic cancer (PC)

MA Tempero, D Cardin, A Biankin, D Goldstein, M Moore, EM O'Reilly, ...

Chemotherapy and Intensity Modulated Radiation Therapy for Locally Advanced Pancreatic Cancer Achieves Prolonged Survival

C Hajj, F Huguet, A Wu, W Shi, Z Zhang, E O'Reilly, C Winston, D Reidy, ...

DNA mismatch repair abnormalities in acinar cell carcinoma of the pancreas: frequency and clinical significance

W Liu, J Shia, M Gönen, MA Lowery, EM O’Reilly, DS Klimstra

Embolization versus embolization and systemic therapy in patients with hepatocellular carcinoma and metastatic disease: A retrospective analysis.

S Kim, KT Brown, Y Fong, SB Solomon, JF Chou, M Capanu, JJ Harding, ...

Evaluation of PARP inhibition as a platinum sparing strategy in Brca2-deficient pancreatic tumors.

MA Lowery, A Lee, E Tobias, P Sung, U Bhanot, R Shakya, T Ludwig, ...

Final Results of a Phase 1B of Omp-59R5 (Anti-Notch2/3/Stem Cell Antibody) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P+ Gem) in Patients (Pts) with Untreated …

J Bendell, AL Cohn, L Smith, JH Strickler, WL Gluck, WG Schmidt, ...

FOLFIRINOX induction therapy for stage III pancreatic adenocarcinoma

E Sadot, A Duossot, EM O'Reilly, M Gönen, TP Kingham, MI D'Angelica, ...

Gemcitabine-related pneumonitis: Elucidation of risk factors.

IH Sahin, A Geyer, D Kelly, EM O'Reilly

Lymph node ratio is an independent prognostic factor after resection of periampullary malignancies: data from a tertiary referral center in the middle East

AI Shamseddine, D Mukherji, C Melki, E Elias, M Eloubeidi, H Dimassi, ...

Molecular features of BRCA1/2 and PALB2 mutation associated pancreatic cancer (PAC).

MA Lowery, K Timms, V Abkevich, C Neff, A Gutin, JS Lanchbury, ...

Multiplatform molecular profiling of 2,400 pancreatic adenocarcinomas to identify targets for therapeutic intent.

SZ Millis, D Arguello, MA Lowery, EM O'Reilly

Multiplatform profiling of a fibrolamellar carcinoma cohort.

JJ Harding, SZ Millis, EM O'Reilly, L Saltz, GK Abou-Alfa, AP Venook, ...

Outcomes of biliary stents in advanced pancreatic cancer in the era of improved systemic therapy.

W Park, PK Mankal, EM O'Reilly

Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer

KH Yu, M Ricigliano, M Hidalgo, GK Abou-Alfa, MA Lowery, LB Saltz, ...

Pharmacogenomic modeling of pancreatic cancer (PDAC) for prediction of chemotherapy response and resistance in second-line treatment setting.

KH Yu, V Sangar, M Ricigliano, M Hidalgo, EM O'Reilly, GK Abou-Alfa, ...

Phase Ib of anticancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+ Gem) in patients (pts) with untreated metastatic …

EM O'Reilly, LS Smith, JC Bendell, FA Rangwala, W Schmidt, ...

Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC).

EM O'Reilly, MA Lowery, MF Segal, SC Smith, MJ Moore, HL Kindler, ...

The management of locally advanced pancreatic cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 14th ESMO/World Congress on …

T Seufferlein, JL Van Laethem, E Van Cutsem, JD Berlin, M Büchler, ...

Treatment of Metastatic Pancreatic Adenocarcinoma: New Options and Promising Strategies.

MA Lowery, EM O'REILLY

Treatment, outcomes, and clinical trial participation in very elderly patients (pts) with metastatic pancreas cancer (mPC).

D Li, M Capanu, KH Yu, MA Lowery, DP Kelsen, EM O'Reilly

25-hydroxyvitamin D levels and survival in patients with advanced pancreatic cancer (APC): Findings from CALGB 80303.

K Van Loon, K Owzar, C Jiang, HL Kindler, MF Mulcahy, D Niedzwiecki, ...

A giant rectal villous adenoma with a malicious intent

MA Hosn, N Abdel-Hafiez, R Abdel-Wahab, A Al-Ahmadie, A Antar, ...

A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas

JK Lee, M Capanu, EM O'reilly, J Ma, JF Chou, J Shia, SS Katz, ...

A randomized controlled trial of a cardiopulmonary resuscitation video in advance care planning for progressive pancreas and hepatobiliary cancer patients

AS Epstein, AE Volandes, LY Chen, KA Gary, Y Li, P Agre, TT Levin, ...

A young woman with liver cancer

CS Ang, RK Do, A Shamseddine, EM O'Reilly, A Haydar, A Al-Olayan, ...

Adjuvant therapy for pancreas adenocarcinoma

EM O'Reilly

Advanced pancreas and hepatobiliary (PHB) cancer patients’ impressions regarding cardiopulmonary resuscitation (CPR).

AS Epstein, E Shuk, K Gary, EM O'Reilly, AE Volandes

Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3

Ganji PN, Park W, Wen J, Mahaseth H, Landry J, Farris AB, Willingham F, …

c-MET and HGF mRNA Expression in Hepatocellular Carcinoma: Correlation with Clinicopathological Features and Survival

CSP Ang, MY Sun, DF Huitzil-Melendez, JFL Chou, M Capanu, ...

Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium

CS Ang, RK Kelley, MA Choti, DP Cosgrove, JF Chou, D Klimstra, ...

Crosstalk from survival to necrotic death coexists in DU-145 cells by curcumin treatment

Kang D, Park W, Lee S, Kim JH, Song JJ

DNA Mismatch Repair Deficiency in Acinar Cell Carcinoma of the Pancreas: Frequency and Significance

W Liu, J Shia, EM O'Reilly, MA Lowery, PJ Allen, DS Klimstra

DNA resection proteins Sgs1 and Exo1 are required for G1 checkpoint activation in budding yeast

FO Balogun, AW Truman, SJ Kron

Emerging therapies for pancreas neuroendocrine cancers

AR Mahjoub, EM O’Reilly

Evolving panorama of treatment for metastatic pancreas adenocarcinoma

EM O'Reilly

Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression

JM Winter, LH Tang, DS Klimstra, W Liu, I Linkov, MF Brennan, ...

Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer

BM Wolpin, EM O'Reilly, YJ Ko, LS Blaszkowsky, M Rarick, ...

Heat shock protein 90 functional inhibition regulates epithelial to mesenchymal transformation, invasion and migration via NF-kB and HIF-1α signaling in colorectal cancer.

P Ganji, TE Long, PM Mummareddi, W Park, FF Willingham, JC Landry, ...

Hereditary metabolic diseases (HMDs) in adult practice in Ireland: a preliminary assessment

L Morrissey, CA Tiernan, D Lambert, E O’Reilly, EP Treacy

Identification of germline genetic mutations in patients with pancreatic adenocarcinoma.

EE Salo-Mullen, EM O'Reilly, DP Kelsen, MA Lowery, KH Yu, ...

Management of a patient diagnosed with pancreatic cancer and myelodysplastic syndrome

E Won, HY Kenneth, A Shamseddine, L Saltz, D Mukherjee, A Haydar, ...

Modified GTX as Second-Line Chemotherapy in Advanced Pancreatic Cancer

H Dbouk, H Ajouz, A Shamseddine, D Mukherji, EM O'Reilly, A Haydar, ...

New perspectives of curcumin in cancer prevention

Park W, Amin ARMR, Chen ZG, Shin DM